Patent · US Active

Anti-C5A binding moieties with high blocking activity

US9073983B2 · kind B2 · utility

12Cited by

1References

16Claims

0Family size

Assignee

InflaRx GmbH · DE

Inventors

Renfeng Guo · Ann Arbor, US
Niels Cristoph Riedemann · Jena, DE
Yan Li · Tallahassee, US
Beifen Shen · Beijing, CN

Key dates

Filing date	Jun 27, 2014
Grant date	Jul 7, 2015
Priority date	—
Expiry date	Jun 27, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.